Overview

A cell membrane is made up of phospholipids. Sphingo, often called Sphingolipids, is a class of lipids and is also a component of the cell membrane. This lipid plays a crucial role in cell structural integrity and signalling. The Sphingolipid found in the myelin sheath, is an extended and modified plasma membrane covered around to protect nerve cells known as Sphingomyelin.

Acid Sphingomyelinase (ASM) is an enzyme found in the lysosomes, a cell organelle containing hydrolytic enzymes that degrade large molecules into small ones. ASM plays a crucial role in the metabolism of sphingomyelin. ASM breaks down the sphingomyelin into ceramide and phosphorylcholine within the lysosomes, to maintain lipid homeostasis. Ceramide is a bioactive lipid that regulates cell growth, differentiation, and apoptosis (programmed cell death).

Acid Sphingomyelinase Deficiency (ASMD) also called Niemann-Pick disease A and B is a rare autosomal recessive genetic disease, caused by mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene located in chromosome 11p15.4 leading to strongly decreased activity of acid sphingomyelinase present in the lysosomes and hence metabolism into ceramide and phosphocholine get prohibited leading to accumulation of Sphingomyelin in the lysosomes mainly of macrophages cell. This lipid gets heavily piled up in macrophages and causes a foamy appearance. This can be found in several tissues, especially the spleen, liver, and lungs.

Overview of ASMD Types (Type A, A/B, B)

ASMD Disease is divided into three types:

• Type A also known as infantile neurovisceral ASMD, is associated with rapidly progressing visceral impairment and neurodegeneration, which typically lead to death by the age of 3 years, most often due to respiratory failure
• Type B also known as Chronic Visceral ASMD, a milder, chronic form of neurological degeneration is rare in Type B. The most common symptoms are interstitial lung disease, hepatosplenomegaly, thrombocytopenia, dyslipidemia, delayed growth, shortness of breath, fatigue, and pain. In short, they developed hepatic and pulmonary life-threatening complications
• Type A/B also known as Chronic neurovisceral intermediate ASMD, is an intermediate form between types A and B. It involves mild to severe neurological impairment but progresses slower than Type A. The most common are symptoms related to visceral organs like in Type B

Importance of studying bone and skeletal abnormalities in ASMD

A study was conducted in the US and UK between August 2015 and December 2019, including Pediatric/Adolescent, and adults to analyze the symptoms and impacts on participant type.

Patients reported a wide range of manifestations, most frequently respiratory (90%), abdominal (86%), and musculoskeletal (79%). Musculoskeletal symptoms, including muscle weakness, bone pain, and joint pain, were reported by 12 of 17 adult and 11 of 12 pediatric/adolescent patients Although musculoskeletal symptoms were reported by both patient cohorts, only adult patients reported back pain, and focal pain in the extremities, and muscle cramps, whereas only pediatric/adolescent patients described experiencing poor muscle tone, joint contractions, joint pain, and weak bones. Descriptions by adult patients indicated that these symptoms develop and progress throughout the patient’s lifetime.1

Symptoms such as osteopenia, osteoporosis, and growth retardation can be early signs of ASMD. Addressing  these symptoms can aid in the timely diagnosis and management,  Understanding disease pathophysiology, Monitoring Disease Progression, and Developing therapeutic Strategies helps to improve patient care and outcomes.

Pathophysiology of ASMD

Genetic Basis of ASMD

• Mutations in SMPD1 gene

The Golgi apparatus is the primary site where sphingomyelin synthesis occurs. Once synthesized and modified, sphingomyelin is packaged into vesicles and transported to the plasma membrane. Acidic sphingomyelinase is localized in the lysosomal compartment, the main site of sphingomyelin metabolism. Mammalian cells contain a single gene for ASM known as the SMPD1 gene which controls the synthesis of the Acid Sphingomyelinase enzyme. The mutation of SMPD1 leads to a shortage of Acid sphingomyelinase resulting in the accumulation of lipids, mainly sphingomyelin in various tissues of the body.

• Inheritance patterns

The mutations in the SMPD1 gene, which cause acid sphingomyelinase deficiency (ASMD) are typically inherited and occur due to the changes in the DNA sequence that affect the synthesis of the acid sphingomyelinase enzyme. This is an autosomal recessive trait meaning two copies of each gene, one inherited from each parent. Both parents are the carrier and do not usually exhibit signs of the disorder because individuals have one normal (dominant) copy of the gene and one mutated one (recessive). The recessive gene is suppressed by the dominant gene resulting in carriers i.e., parents are normal without showing symptoms.

Biochemical Impact

• Dysfunction in sphingomyelin metabolism

The deficiency in the ASM leads to suppression of sphingomyelin metabolism resulting in the accumulation of lipid and consequently lipid-loaded cells determined as Foam cells. These are usually macrophages. However, tissue-specific cells are also affected. Lipid-loaded cells lose all their function and die, causing multiple clinical dysfunctions. This foam cell affects the lungs, spleen, bone marrow, lymph nodes, and liver.

• Accumulation of sphingomyelinase and its effects on the body

As we know, the Liver is the main organ that carries metabolic activity. Here, the disruption of the metabolism of sphingomyelin lipid is widely affecting the liver causing hepatomegaly- enlargement of the liver due to accumulation of lipid in the Kupffer cells and hepatocytes. Spleen also gets affected leading to enlargement because the lipid gets accumulated in the macrophages which is a type of white blood cells. The role of the spleen is to digest the old and damaged blood cells. The spleen tries to digest these cells, but cannot be broken down due to enzyme deficiency hence the sphingomyelin gets accumulated in the spleen as well disturbing its function. The lungs contain a large number of alveolar macrophages and also get affected in the same way. The Sphingomyelin which is present around the nerve also widely accumulates leading to neurological impairment. In short, wherever the macrophages are present in the body, the tissue gets affected leading to dysfunctionality.

Bone and Skeletal Abnormalities in ASMD

Mechanisms Leading to Skeletal Abnormalities

Bone and skeletal abnormalities in ASMD occur primarily due to the accumulation of sphingomyelin in bone and bone marrow. Bone marrow is a major site of blood cell production, which also includes macrophages, rich in lysosomes. The macrophages get filled with sphingomyelin leading to the replacement of normal bone marrow cells with lipid-loaded macrophages and simultaneously causing anemia and other blood-related issues. The Sphingomyelin proliferated from bone marrow to bone disrupting the normal balance between bone formation and resorption. The bone cells are filled with lipids leading to bone density (osteopenia) and other skeletal abnormalities.

Types of Skeletal Abnormalities

• Osteopenia and Osteoporosis

Patients with ASMD may develop low bone density (osteopenia) and more severe bone loss (osteoporosis), making bones more susceptible to fracture risk. Children with ASMD may experience delayed growth due to the disruption of normal bone growth processes

• Skeletal Deformities (e.g., scoliosis, kyphosis)

Some patients may develop bone deformities, such as dysostosis multiplex, which is a complex of skeletal abnormalities commonly seen in lysosomal storage disorders, This can include abnormal bone shape and structure, particularly Scoliosis, the spine curves to one side of the body or kyphosis, a excessive forward rounding of upper back.

• Joint Stiffness

Accumulation of sphingomyelin in the joints can lead to stiffness resulting in reduced flexibility, reduced mobility, joint pain, and other complications.

Clinical Manifestations

• Respiratory symptoms- Shortness of breath, cough, chest pain, repeated respiratory infections, and difficulty in breathing
• Musculoskeletal symptoms- muscle weakness, bone pain, joint pain, back pain, poor muscle tone, focal pain in extremities, muscle cramps
• Gastrointestinal symptoms- stomach upset, nausea, vomiting and diarrhoea
• Abdominal symptoms- abdominal pain, enlarged or distended abdomen.
• Headaches
• Fatigue
• Excessive bleeding or bruising

Diagnostic Approaches

• Imaging Techniques
  • X-rays: X-rays showing bone enlargement, bone deformities, and thin cortical bones and to check interstitial lung disease.
  • Ultrasound: Abdominal ultrasound to assess the extent of hepatosplenomegaly
  • MRI: Particularly used to detect the liver and spleen enlargement
• Bone Densitometry (DEXA scan)
  • To check Bone Mineral Density (BMD) to diagnose symptoms like osteopenia and osteoporosis:
    • Osteopenia: T-score between -1.0 and -2.5
    • Osteoporosis: T-score is lesser or equal to -2.5
• Enzyme activity assays
  • Measurement of acid sphingomyelinase activity in leukocytes (WBCs) or cultured skin fibroblasts is the gold standard for diagnosing ASMD. Lipid profile analysis may reveal elevated levels of sphingomyelin in the blood. Elevated serum chitotriosidase is an indication of macrophage activation that can also help detect  ASMD
• Genetic testing
  • Genetic testing is performed to identify mutations in the SMPD1 gene. The carrier i.e, parent and prenatal testing in families with a known mutation can also be performed

Management and Treatment

Pharmacological Interventions

• Enzyme replacement therapy (ERT)

Enzyme replacement therapy has emerged as a significant treatment to treat ASMD, particularly in type B or type A/B of the disease. The therapy involves replacing the deficient enzyme with a synthetic version to reduce the smoothly carried out metabolism of sphingomyelin.

Olipudase alfa is the recombinant human acid sphingomyelinase (rhASM) used in ERT. It is typically administered intravenously, starting the regimen with a low dose. It is not a cure for ASMD however it significantly reduces symptoms and improves function.

• Bone-targeted therapies 

While ERT primarily addresses the systemic symptoms of ASMD, bone-targeted therapies can be considered to manage bone-specific tissues.

• Bisphosphonates: Bisphosphonates inhibit bone resorption by osteoclasts, thereby increasing bone density and reducing the risk of fractures
• Calcium and Vitamin D: Adequate calcium and vitamin D are essential for bone health. Vitamin D helps in the absorption of calcium, which is necessary to maintain bone density
• Denosumab:Denosumab is a monoclonal antibody that inhibits RANKL, a protein involved in the formation and osteoclasts (cells that break down bone)
• Teriparatide: Teriparatide is a recombinant form of parathyroid hormone that promotes the activity of osteoblasts (bone-forming cells)

Non-Pharmacological Approaches

Physical therapy and rehabilitation

• Exercises: Exercises such as yoga, weight lifting, and low-impact exercises like walking help to improve muscle strength, particularly in lower limbs and can help maintain mobility
• Breathing Exercises: Techniques such as deep breathing, incentive spirometry, and chest physiotherapy can help maintain lung function
• Manual Therapy: Techniques like massage and soft tissue mobilization can help to reduce muscle pain
• Supportive Devices and Adaptive Equipment: Orthotics and braces can help stabilize joints, improve walk, and reduce the risk of falls

Nutritional support and lifestyle modifications

• Balanced Diet: A diet rich in essential nutrients, vitamins, and minerals can support overall health. Add specific supplements such as Vitamin A, D, E, and K especially if fat absorption is impaired. Omega-3 fatty acids to support cardiovascular health. Add calcium-rich food to your diet
• Avoid Alcohol Consumption: Already the liver gets damaged in ASMD due to the accumulation of sphingomyelin leading to hepatomegaly, and drinking alcohol can cause liver failure
• Exercises: Start with low impact like walking, and gradually increase with yoga, strengthening training, and weight lifting based on the severity of the disease

Summary

Acid Sphingomyelinase Deficiency is a rare disease caused by the accumulation of sphingomyelin, a lipid that adversely affects multiple organs. There is no such medical treatment to cure right away. The ERT is the only treatment for a lifelong. Adopting a balanced diet, including exercises will not cure the disease but help to prevent pain, minimize the illness and improve quality of life.